Valera's Vantas Prostate Cancer Implant To Launch By Year-End

Valera is assembling a 50-rep urology sales force and building inventory for histrelin. Company hopes to distinguish Vantas from the other 12-month implant, Bayer/Alza's Viadur, based on the design of the delivery system.